Literature DB >> 29686154

Population Pharmacokinetic Model for Vancomycin Used in Open Heart Surgery: Model-Based Evaluation of Standard Dosing Regimens.

Saeed A Alqahtani1,2, Abdullah S Alsultan3,2, Hussain M Alqattan4, Ahmed Eldemerdash5, Turki B Albacker4.   

Abstract

The purpose of this study was to investigate the population pharmacokinetics of vancomycin in patients undergoing open heart surgery. In this observational pharmacokinetic study, multiple blood samples were drawn over a 48-h period of intravenous vancomycin in patients who were undergoing open heart surgery. Blood samples were analyzed using an Architect i4000SR immunoassay analyzer. Population pharmacokinetic models were developed using Monolix 4.4 software. Pharmacokinetic-pharmacodynamic (PK-PD) simulations were performed to explore the ability of different dosage regimens to achieve the pharmacodynamic targets. A total of 168 blood samples were analyzed from 28 patients. The pharmacokinetics of vancomycin are best described by a two-compartment model with between-subject variability in clearance (CL), the volume of distribution of the central compartment (V1), and volume of distribution of the peripheral compartment (V2). The CL and the V1 of vancomycin were related to creatinine CL (CLCR), body weight, and albumin concentration. Dosing simulations showed that standard dosing regimens of 1 and 1.5 g failed to achieve the PK-PD target of AUC0-24/MIC > 400 for an MIC of 1 mg/liter, while high weight-based dosing regimens were able to achieve the PK-PD target. In summary, the administration of standard doses of 1 and 1.5 g of vancomycin two times daily provided inadequate antibiotic prophylaxis in patients undergoing open heart surgery. The same findings were obtained when 15- and 20-mg/kg doses of vancomycin were administered. Achieving the PK-PD target required higher doses (25 and 30 mg/kg) of vancomycin.
Copyright © 2018 American Society for Microbiology.

Entities:  

Keywords:  Monte Carlo simulation; PK-PD; open heart surgery; population pharmacokinetics; prophylaxis; vancomycin

Mesh:

Substances:

Year:  2018        PMID: 29686154      PMCID: PMC6021682          DOI: 10.1128/AAC.00088-18

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  48 in total

1.  Population pharmacokinetics of vancomycin in adult and geriatric patients: comparison of eleven approaches.

Authors:  J L Sánchez; A R Dominguez; J R Lane; P O Anderson; E V Capparelli; J M Cornejo-Bravo
Journal:  Int J Clin Pharmacol Ther       Date:  2010-08       Impact factor: 1.366

2.  Monte Carlo simulation analysis of ceftobiprole, dalbavancin, daptomycin, tigecycline, linezolid and vancomycin pharmacodynamics against intensive care unit-isolated methicillin-resistant Staphylococcus aureus.

Authors:  Ahmed Hamed Salem; George G Zhanel; Safaa A Ibrahim; Ayman M Noreddin
Journal:  Clin Exp Pharmacol Physiol       Date:  2014-06       Impact factor: 2.557

3.  A Quasi-Experiment To Study the Impact of Vancomycin Area under the Concentration-Time Curve-Guided Dosing on Vancomycin-Associated Nephrotoxicity.

Authors:  Natalie A Finch; Evan J Zasowski; Kyle P Murray; Ryan P Mynatt; Jing J Zhao; Raymond Yost; Jason M Pogue; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2017-11-22       Impact factor: 5.191

4.  Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections.

Authors:  Pamela A Moise-Broder; Alan Forrest; Mary C Birmingham; Jerome J Schentag
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation.

Authors:  Hussain Mulla; Suneel Pooboni
Journal:  Br J Clin Pharmacol       Date:  2005-09       Impact factor: 4.335

6.  Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  George Sakoulas; Pamela A Moise-Broder; Jerome Schentag; Alan Forrest; Robert C Moellering; George M Eliopoulos
Journal:  J Clin Microbiol       Date:  2004-06       Impact factor: 5.948

Review 7.  Management of methicillin-resistant Staphylococcus aureus bacteremia.

Authors:  Sara E Cosgrove; Vance G Fowler
Journal:  Clin Infect Dis       Date:  2008-06-01       Impact factor: 9.079

8.  Effect of cardiopulmonary bypass on vancomycin and netilmicin disposition.

Authors:  K J Klamerus; K A Rodvold; N A Silverman; S Levitsky
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

9.  Risk of surgical site infection, acute kidney injury, and Clostridium difficile infection following antibiotic prophylaxis with vancomycin plus a beta-lactam versus either drug alone: A national propensity-score-adjusted retrospective cohort study.

Authors:  Westyn Branch-Elliman; John E Ripollone; William J O'Brien; Kamal M F Itani; Marin L Schweizer; Eli Perencevich; Judith Strymish; Kalpana Gupta
Journal:  PLoS Med       Date:  2017-07-10       Impact factor: 11.069

10.  Clinical and financial outcomes due to methicillin resistant Staphylococcus aureus surgical site infection: a multi-center matched outcomes study.

Authors:  Deverick J Anderson; Keith S Kaye; Luke F Chen; Kenneth E Schmader; Yong Choi; Richard Sloane; Daniel J Sexton
Journal:  PLoS One       Date:  2009-12-15       Impact factor: 3.240

View more
  5 in total

Review 1.  An Update on Population Pharmacokinetic Analyses of Vancomycin, Part I: In Adults.

Authors:  Abdullah Aljutayli; Amélie Marsot; Fahima Nekka
Journal:  Clin Pharmacokinet       Date:  2020-06       Impact factor: 6.447

2.  Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units.

Authors:  Zhong Lin; Dan-Yang Chen; Yan-Wu Zhu; Zheng-Li Jiang; Ke Cui; Sheng Zhang; Li-Hua Chen
Journal:  Sci Rep       Date:  2021-01-29       Impact factor: 4.379

3.  Population pharmacokinetic model of vancomycin in postoperative neurosurgical patients.

Authors:  Shifeng Wei; Dongjie Zhang; Zhigang Zhao; Shenghui Mei
Journal:  Front Pharmacol       Date:  2022-09-26       Impact factor: 5.988

4.  Comparison of area under the curve for vancomycin from one- and two-compartment models using sparse data.

Authors:  Nyein Hsu Maung; Janthima Methaneethorn; Thitima Wattanavijitkul; Tatta Sriboonruang
Journal:  Eur J Hosp Pharm       Date:  2021-07-20

Review 5.  Clinical Practice Guidelines for Therapeutic Drug Monitoring of Vancomycin in the Framework of Model-Informed Precision Dosing: A Consensus Review by the Japanese Society of Chemotherapy and the Japanese Society of Therapeutic Drug Monitoring.

Authors:  Kazuaki Matsumoto; Kazutaka Oda; Kensuke Shoji; Yuki Hanai; Yoshiko Takahashi; Satoshi Fujii; Yukihiro Hamada; Toshimi Kimura; Toshihiko Mayumi; Takashi Ueda; Kazuhiko Nakajima; Yoshio Takesue
Journal:  Pharmaceutics       Date:  2022-02-23       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.